Room for growth: Real-world maintenance and treatment PARP inhibitor use in BRCAm ovarian cancer patients

被引：0
|
作者：
Lee, Sarah [1 ]
Smith, Maria [2 ]
Monestime, Gianina [2 ]
Pothuri, Bhavana [2 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] NYU Langone Hlth, New York, NY USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
508
引用
收藏
页码：S268 / S269
页数：2
相关论文
共 50 条
  • [1] PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China
    Chen, Jinghong
    Zhang, Mengpei
    Li, Kemin
    Duan, Yuanqiong
    Zeng, Jing
    Li, Qingli
    Wang, Danqing
    Song, Liang
    Li, Qintong
    Yin, Rutie
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [2] PARP INHIBITOR MAINTENANCE IN PLATINUMSENSITIVE OVARIAN CANCER: A SINGLE-CENTER REAL-WORLD EXPERIENCE
    Das, Chandan
    Prakash, Gaurav
    Bagga, Rashmi
    Rai, Bhavna
    Prasad, G. R. V.
    Saha, S. C.
    Suri, V.
    Jain, V.
    Kalra, Jaswinder
    Ghoshal, Sushmita
    Srinivasan, Radhika
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A135 - A135
  • [3] Evaluating the real-world impact of first line PARP inhibitor maintenance therapy in patients with BRCA mutated ovarian tumors
    Piedimonte, Sabrina
    Hogen, Liat
    Atenafu, Eshetu
    Laframboise, Stephane
    Ferguson, Sarah
    Bouchard-Fortier, Genevieve
    Bernardini, Marcus
    May, Taymaa
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S140 - S141
  • [4] A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients
    Chung-Shien Lee
    Hernandez, Jennifer
    Liang, Connie
    Leung, Ashley
    Stefanov, Dimitre G.
    Cheng, Kit
    John, Veena
    JOURNAL OF PHARMACY PRACTICE, 2023, 36 (05) : 1134 - 1141
  • [5] Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada
    Guan, Qi
    Aktar, Suriya J.
    Pataky, Reka E.
    Stephen, Mariet Mathew
    Marques, Maud
    Gambaro, Karen
    Rachedi, Kahina
    Forster, Katharina
    Strub, Samara
    Stock, David
    de Leseleuc, Louis
    Cheung, Winson Y.
    Peacock, Stuart
    Farrer, Christie
    Gavura, Scott
    Tadrous, Mina
    Grant, Robert C.
    Chan, Kelvin K. W.
    CURRENT ONCOLOGY, 2024, 31 (06) : 3591 - 3602
  • [6] Real-world use, tolerability, and dose modifications of PARP inhibitors in ovarian cancer.
    O'Malley, David M.
    Arend, Rebecca Christian
    Alam, Naufil
    Ozgoren, Ozan
    McLaurin, Kimmie K.
    Long, Grainne H.
    Banerjee, Susana N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Real-world evaluation of PARP inhibitor tolerability in advanced ovarian cancer: Retrospective US cohort study
    Simmons, Daniel
    Blank, Stephanie
    Nagar, Saurabh
    Nham, Tram
    Long, Grainne
    Davis, Keith
    Wetherill, Graham
    Munley, Jiefen
    McLaurin, Kimmie
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S262 - S263
  • [8] PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience
    Agarwal, Amit
    Baghmar, Saphalta
    Dodagoudar, Chandragouda
    Qureshi, Suhail
    Khurana, Aseem
    Vaibhav, Vikas
    Kumar, Guresh
    JCO GLOBAL ONCOLOGY, 2021, 7 : 506 - 511
  • [9] Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment
    Havrilesky, Laura J.
    Lim, Stephanie
    Ehrisman, Jessie A.
    Lorenzo, Amelia
    Secord, Angeles Alvarez
    Yang, Jui-Chen
    Johnson, F. Reed
    Gonzalez, Juan Marcos
    Reed, Shelby D.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 561 - 567
  • [10] Real-world treatment of niraparib as maintenance therapy in patients newly diagnosed advanced ovarian cancer in Japan
    Shimada, Muneaki
    Kuwahara, Yuki
    Kuwabara, Hiroyo
    Kato, Ai
    Tabata, Tsutomu
    ANNALS OF ONCOLOGY, 2023, 34 : S1440 - S1440
12345